C12N 2760/12211
Phlebovirus
Official title: Phlebovirus, e.g. Rift Valley fever virus
C12N2760/12211 (Phlebovirus) appears on 33 US grants and 56 published applications in this corpus.
Search patents in C12N- Granted patents
- 33
- Published applications
- 56
- Assignees
- 45
- Inventors
- 132
- Latest grant
- 24 Mar 2026
Filings by year
| Year | Granted patents | Published applications |
|---|---|---|
| 1988 | 1 | 0 |
| 1989 | 0 | 0 |
| 1990 | 0 | 0 |
| 1991 | 0 | 0 |
| 1992 | 0 | 0 |
| 1993 | 0 | 0 |
| 1994 | 0 | 0 |
| 1995 | 0 | 0 |
| 1996 | 0 | 0 |
| 1997 | 0 | 0 |
| 1998 | 0 | 0 |
| 1999 | 0 | 0 |
| 2000 | 0 | 0 |
| 2001 | 0 | 0 |
| 2002 | 0 | 0 |
| 2003 | 0 | 0 |
| 2004 | 0 | 2 |
| 2005 | 0 | 1 |
| 2006 | 0 | 3 |
| 2007 | 0 | 1 |
| 2008 | 0 | 0 |
| 2009 | 0 | 3 |
| 2010 | 0 | 2 |
| 2011 | 1 | 3 |
| 2012 | 0 | 1 |
| 2013 | 0 | 3 |
| 2014 | 2 | 5 |
| 2015 | 4 | 4 |
| 2016 | 3 | 6 |
| 2017 | 6 | 0 |
| 2018 | 2 | 2 |
| 2019 | 1 | 1 |
| 2020 | 2 | 1 |
| 2021 | 1 | 8 |
| 2022 | 0 | 0 |
| 2023 | 5 | 4 |
| 2024 | 1 | 4 |
| 2025 | 3 | 1 |
| 2026 | 1 | 1 |
By publication year. Applications have been published since 2001. 2026 runs to 8 Oct.
Subgroups
Granted patents
- C12N 2760/12234Use of virus or viral component as vaccineIndexing code25
- C12N 2760/12221Viruses as suchIndexing code13
- C12N 2760/12222New viral proteins or individual genes, new structural or functional aspects ofIndexing code10
- C12N 2760/12233Use of viral protein as therapeutic agent other than vaccineIndexing code4
- C12N 2760/12261Methods of inactivation or attenuationIndexing code4
- C12N 2760/12223Virus like particles [vlp]Indexing code3
- C12N 2760/12251Methods of production or purification of viral materialIndexing code3
- C12N 2760/12271Demonstrated in vivo effectIndexing code3
All 12 subgroupsShow fewer
Recent patents
- Attenuated variant of the rift valley fever virus, composition comprising same, and uses thereof24 Mar 2026US 12,584,116 B2Consejo Superior De Investigaciones Cientificas (Csic)
- Severe fever with thrombocytopenia syndrome virus9 Sep 2025US 12,409,216 B2I.D.Bio.
- Bunyavirales vaccine26 Aug 2025US 12,397,048 B2CureVac AG
- DNA vaccine against crimean-congo hemorrhagic fever virus (CCHFV)13 May 2025US 12,296,001 B2The Wistar Institute of Anatomy and Biology
- Mammal-specific growth-defective arbovirus24 Sep 2024US 12,098,393 B2TenGen Biomedical Company
- Bunyavirales vaccine2 Apr 2026US 2026/0091101 A1CureVac AG
- Monoclonal Antibody A38 Against Rift Valley Fever Virus and Use11 Sep 2025US 2025/0282851 A1Academy of Military Medical Science, PLA
- Multivalent viral particles21 Nov 2024US 2024/0382580 A1Cornell University
- Identification and Attenuation of the Immunosuppressive Domains in Fusion Proteins of Enveloped RNA Viruses9 May 2024US 2024/0150409 A1ISD Immunotech ApS
- Bovine herpesvirus type 1 (bohv-1) quadruple gene deleted mutant14 Mar 2024US 2024/0084325 A1The Boards of Supervisors of Louisiana State University and Agricultural and Mechanical College
Most cited
By later US patents
- Virus-like particles, methods of preparation, and immunogenic compositions15US 9,045,727 B2Emory University · 2015
- Bunyavirales vaccine9US 11,602,557 B2Cure Vac SE · 2023
- Antiviral rift valley fever virus peptides and methods of use8US 9,556,237 B2The United States of America, as represented by the Secretary of the Army, on behalf of the U.S. Army Medical Research Institute of Infectious Diseases · 2017
- Vaccines against rift valley fever virus5US 4,735,800 AMolecular Genetics, Inc. · 1988
- Reverse genetic system for rift valley fever virus and uses thereof5US 8,084,248 B2Board of Regents, The University of Texas System · 2011